Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasms × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 3 Neuroblastoma 2 Neoplasms 2 Lung Neoplasms 2 Glioblastoma 2 Recurrence 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Glioma 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Castration-resistant Prostate Cancer 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1 Advanced Cancers 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Paclitaxel 67 Trastuzumab 65 Fulvestrant 45 Cyclophosphamide 45 Capecitabine 36 pembrolizumab 34 Lapatinib 34 Docetaxel 34 palbociclib 29 Carboplatin 27 Letrozole 25 Doxorubicin 20 Gemcitabine 19 olaparib 18 Everolimus 17 abemaciclib 16 Bevacizumab 16 Ado-Trastuzumab Emtansine 16 pertuzumab 15 Vinorelbine 15 Magnetic Resonance Spectroscopy 15 Cisplatin 15 ribociclib 14 exemestane 14 Taxes 14 Radiotherapy 14 Nivolumab 13 130-nm albumin-bound paclitaxel 12 veliparib 11 Filgrastim 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡